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a b s t r a c t
Pre-exposure prophylaxis (PrEP) strategies utilizing anti-retroviral drugs show considerable promise for
HIV prevention. However there is insufﬁcient pharmacokinetic (PK) data on drug concentrations
required for protection at the relevant mucosal tissues where the infection is initiated. Here we
evaluated the utility of a humanized mouse model to derive PK data on two leading drugs, the RT
inhibitor Tenofovir (TFV) and CCR5 inhibitor Maraviroc (MVC). Following oral dosing, both the drugs and
the intracellular active TFV-diphosphate could be detected in vaginal, rectal and intestinal tissues. The
drug exposures (AUC24 h) were found to be higher in vaginal tissue compared to plasma with even higher
levels detected in rectal and intestinal tissues. The overall trends of drug concentrations seen in
humanized mice reﬂect those seen in the human thus establishing the utility of this model
complementing the present non-human primate (NHP) models for future pre-clinical evaluations of
promising HIV PrEP drug candidates.
& 2014 Elsevier Inc. All rights reserved.
Introduction
An estimated 34 million people worldwide were living with
HIV in 2011 (UNAIDS, 2013). The same year 2.5 million new
infections were reported, along with 1.7 million HIV related deaths
(UNAIDS, 2013). While the current highly active antiretroviral
therapy (HAART) regimens efﬁciently control the infection and
delay progression to AIDS, there is no complete cure due to HIV
viral latency (Ruelas and Greene, 2013). In addition, prolonged
therapy can have other problems, including drug resistance and
drug toxicity (Pennings, 2013). Preventive vaccines would be ideal
to control the spread of HIV/AIDS, however no success thus far has
been achieved (Excler et al., 2014). Therefore, other approaches are
urgently needed to confer protection. In this regard antiretroviral
(ARV) drug-based pre-exposure prophylaxis (PrEP) strategies pre-
sent a practical preventative alternative (Heneine and Kashuba,
2012; Nicol and Kashuba, 2010; Romano et al., 2013). Two types of
PrEP strategies are currently being pursued with promising results
(Heneine and Kashuba, 2012; Nicol and Kashuba, 2010; Romano et
al., 2013). The ﬁrst involves oral systemic administration of ARVs,
while the second consists of topical vaginal or rectal application of
ARV-containing gels with both strategies designed to prevent HIV
sexual transmission by mucosal routes. Indeed, ﬁeld clinical trials
had shown promising results with the use of reverse transcriptase
inhibitor Tenofovir (TFV) as a microbicide gel in preventing HIV
vaginal transmission whereas TFV alone or in combination with
Emtricitabine (Truvada) administered orally also provided signiﬁ-
cant protection (Abdool Karim et al., 2010; Grant et al., 2010).
While protection afforded by these above approaches is pro-
mising, inconsistencies were found regarding the levels of protec-
tion in different clinical trials (Abdool Karim et al., 2010; Baeten et
al., 2012; Grant et al., 2010; Karim et al., 2011; Thigpen et al., 2012;
Van Damme et al., 2012). In the CAPRISA trial, 44% protection was
achieved with a TFV microbicide gel, whereas in the VOICE trial,
which also used a TFV microbicide gel, the trial was discontinued
before conclusion because of a lack of protection (Abdool Karim et
al., 2010; McEnery, 2011; van der Straten et al., 2012). In the IPrEx
trial, oral administration of Truvada showed a 44% reduction in
HIV infection in men who have sex with men (MSM) (Grant et al.,
2010). The FEM-PrEP trial, also with oral Truvada, was stopped
early due to lack of efﬁcacy in high-risk female population (Van
Damme et al., 2012). The TDF2 study also evaluated oral Truvada in
men and women and reported a 63% reduction in HIV infection
acquisition (Thigpen et al., 2012). The Partners PrEP study, looking
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Fig. 1. PK analysis of orally administered TFV in hu- and non-hu mice. Mice were administered TFV by oral gavage (human equivalent dose 61.5 mg/kg) for 5 days. Post-last
dose, plasma and tissue samples were collected at different time points and drug concentrations were determined (ng/ml or ng/g). A1 (hu-mice), and A2 (non-hu mice).
Composite medians and interquartile ranges (IQR) for plasma, vaginal, rectal and intestinal tissue (colon). B1–E1 (hu-mice), and B2–E2 (non-hu mice). Individual data points
(n¼5 hu-mice, n¼3 non-hu mice) for plasma (B), vaginal (C), rectal (D) and intestinal tissue (colon) (E) with composite medians (IQR) are shown.
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at serodiscordant couples, showed a 67% reduction in HIV-1
incidence with oral TFV and a 75% reduction with Truvada
(Baeten et al., 2012). Additional clinical trials are being conducted
in various test populations and results are being awaited (Cohen et
al., 2013). The above conﬂicting results with regard to variable
levels of protection are attributed to differences in ARV dosing
regimens, trial designs and target populations, sexual practices
and behavioral patterns affecting adherence. A major factor that
contributes to protection against HIV is the proper drug concen-
tration to be reached in the target mucosal tissues, such as vaginal
and rectal tissue. Tissue drug concentrations are affected by
variables such as ARV dose, mode and frequency of administration,
tissue permeability and protein binding, as well as drug half-life.
Consequently, pharmacokinetic (PK) studies that focus on the
mucosal compartments are critical for the future success of PrEP
strategies.
Animal models have played crucial role in therapeutic drug
development to derive important preclinical data (Akkina, 2013;
Veazey, 2013). With regard to assessing HIV PrEP strategies non-
human primates (NHP) models have been extremely useful in
setting the stage for early human clinical trials (Evans and Silvestri,
2013; Fennessey and Keele, 2013). For example, TFV was success-
fully evaluated as both oral and topical PrEP in rhesus macaque
studies (Garcia-Lerma et al., 2010, 2008; Nuttall et al., 2012; Parikh
et al., 2009). The HIV entry inhibitor maraviroc (MVC) was
evaluated similarly in NHP (Forbes et al., 2011; Malcolm et al.,
2013). However, a number of limitations are apparent with NHP
models. First of all, they are expensive and use of large numbers of
animals often is not feasible. In addition, SIV or SHIV, not HIV
itself, must be applied as a challenge virus thus precluding NHP
use for testing drugs speciﬁcally developed against HIV. In this
context, humanized mice (hu-mice) with a transplanted human
immune system have become amenable to test various HIV
prevention approaches (Akkina, 2013; Denton and Garcia, 2011).
Two new generation humanized mouse models are currently
available. The hu-HSC humanized mouse model such as RAG-hu
employs engraftment of human hematopoietic stem cells (HSC)
into newborn immunodeﬁcient (Rag1/ or Rag2 /γc /) mice
whereas the BLT mouse model is derived by transplantation of
human fetal thymus tissue, liver tissue and HSC (Akkina, 2013;
Denton and Garcia, 2011). Both models harbor human immune
cells in mucosal sites such as vaginal and rectal tissue, and are
susceptible to HIV infection via these routes thus mimicking key
aspects of viral mucosal transmission (Berges et al., 2008; Denton
and Garcia, 2012; Nischang et al., 2012). Both topical and systemic
PrEP strategies employing ARVs have been successfully tested
using these models (Chateau et al., 2013; Denton et al., 2011;
Neff et al., 2011, 2010). The drugs tested include TFV, MVC, RT
inhibitor Emticitabine (FTC) and integrase inhibitor Raltegravir
(RAL). Pharmacokinetic and pharmacodynamic (PK/PD) analyses of
ARVs in relevant tissue compartments and blood plasma are
important to ascertain the relationship between systemic and
local concentrations achieved after drug application and to corre-
late with antiviral efﬁcacy (Romano et al., 2013; Thompson et al.,
2013). Such data can inform the level and duration of effective
drug dosing for HIV prevention. While a number of previous
studies established the utility of humanized mouse models for
efﬁcacy testing of new PrEP strategies and more recently drug
distribution in lymphoid tissues (Chateau et al., 2013; Choudhary
et al., 2009; Denton et al., 2008, 2014, 2011; Neff et al., 2011, 2010),
no PK studies using these models in the context of mucosal tissues
have been described.
Here we evaluated the utility of hu-mice to derive PK data
employing two different classes of ARVs–TFV and MVC. Our results
Table 1
PK parameters for Tenofovir and Tenofovir Diphosphate in humanized and non-humanized mice.
TFV (hu mice) Plasma Vaginal tissue Rectal tissue Intestinal tissue
Cmax
a 1990 729 56,732 74,677
Median (IQR) (898–3310) (581–6739) (21,746–164,561) (55,008–288,570)
Tmax 2 h 2 h 2 h 2 h
AUCb 11,251 14,946 1106 1.43106
t ½c 17 9 13.5 13.9
TFV-DP (hu mice)
Cmax
a NA BLQd 604 8841
Median (IQR) (336–6466) (322–28,175)
Tmax NA / 2 h 8 h
AUC b NA / 70,194 172,167
t ½c NA / 22.2 3.5
TFV (non-hu mice)
Cmax
a 1550 785 76,520 50,334
Median (IQR) (1200–1,990) (224–819) (50,493–78,415) (38,112–72,930)
Tmax 2 h 8 h 8 h 8 h
AUCb 17,278 9671 1.3106 1106
t ½c 15 6.3 53 61.6
TFV-DP (non-hu mice)
Cmax
a NA BLQ 198 119
Median (IQR)
Tmax NA / 24 h 8 h
AUCb NA / 3188 2414
t ½ c NA / /e 45.3
BLQ - below the limit of quantiﬁcation; NA - not applicable.
a Median (interquartile range, IQR), ng/ml or ng/g.
b Area under the curve (AUC)48 h for plasma (ng h/ml); AUC24 h for tissues (ng h/g).
c Half-life (t½, h).
d TFV-DP detected in 2 samples in humanized mice - once at 2 h and once at 24 h.
e No elimination phase.
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show that both ARVs can be readily measured in blood plasma and
mucosal compartments encompassing vaginal, rectal and intest-
inal tissues. The overall drug distribution kinetics in this system
were found to be similar to humans thus validating this model for
future studies employing more complex combinatorial PrEP dos-
ing regimens.
Results
TFV and TDP concentrations in plasma and mucosal tissue
compartments
To compare the differential drug distribution and accumula-
tion, TFV concentrations were measured in plasma and mucosal
tissue compartments namely, vaginal, rectal and intestinal tissues
at 2, 8, 24 h post-last dose. In addition, plasma concentrations
were also determined at 48 h. The composite pharmacokinetic
data on drug concentrations at various time points in different
tissue compartments and plasma of hu-mice are presented in
Fig. 1A1 whereas the data for individual hu-mice (5 mice per time
point) for each of the compartments at different times are
presented in Fig. 1B1–E1. Similarly, composite pharmacokinetic
data and data for individual non-hu mice (3 mice per time point)
are presented in Fig. 1A2 and B2–E2, respectively. Data on TFV
Cmax, Tmax, half-life (t1/2) and area under the curve (AUC) are
presented in Table 1 for both hu and non-hu mice.
TFV was easily detected in all compartments at all time points
(Fig. 1A–E). In hu-mice, highest concentrations in plasma were
detected at 2 h post dosing (Cmax 1990 ng/ml) with a terminal
elimination phase occurring by approximately 24 h. The AUC48 h
for plasma was 11,251 ng h/ml. The median t1/2 in plasma was 17 h.
In vaginal tissues, Cmax was at 2 h (729 ng/g) with a gradual
elimination by 24 h. Vaginal tissue AUC24 h was 14,946 ng h/g
and TFV concentration in this tissue compartment was higher
than in plasma at 8 h and 24 h. Half-life of TFV in vaginal tissue
was 9 h. Rectal tissue Cmax was 56,732 ng/g at 2 h with an AUC24 h
of 1106 ng h/g and t1/2 of 13.5 h. In intestinal tissue, Cmax was
74,677 ng/g at 2 h. The AUC was 1.43106 ng h/g and tissue t1/2
was 13.9 h. The overall TFV exposure indicated by AUC24 h was the
highest in intestinal tissue followed by rectal tissue, vaginal tissue
and plasma. The AUC24 h tissue:plasma ratios for TFV were 1.5 for
vaginal, 99 for rectal and 141.7 for intestinal tissue. TFV exhibited
higher exposures in rectal and intestinal tissue as a group, with
concentrations one to two logs higher compared to vaginal tissue
and plasma at all time points analyzed (Fig. 1, Table 1). Half-life
values of 13.5 h and 13.9 h in rectal and intestinal tissue respec-
tively suggest similar elimination kinetics from these two tissues
with slower elimination rate compared to vaginal tissue (t1/2 9 h).
In comparative experiments using non-hu mice, highest TFV
concentrations in plasma were also detected at 2 h post dosing
(median Cmax 1550 ng/ml) with a terminal elimination phase by
24 h. The AUC48 h for plasma was 17,278 ng h/ml. The median t1/2
in plasma was 15 h. In vaginal tissues, Cmax was at 8 h (785 ng/g)
with a gradual elimination by 24 h. Vaginal tissue AUC24 h was
9671 ng h/g and TFV concentration in this tissue compartment
was lower than in plasma at 2 h and similar to plasma at 8 h and
24 h. Half-life of TFV in vaginal tissue was 6.3 h. Rectal tissue Cmax
was 76,520 ng/g at 8 h with an AUC24 h of 1.3 106 ng h/g and t1/2
of 53 h. In intestinal tissue, Cmax was 50,334 ng/g at 8 h. The AUC
was 1106 ng h/g and t1/2 was 61.6 h. The overall TFV exposure in
non-hu mice, indicated by AUC24 h was the highest in rectal tissue
followed by intestinal tissue, plasma and vaginal tissue. The
AUC24 h tissue:plasma ratios for TFV in non-hu mice were 0.7 for
vaginal, 95 for rectal and 77.5 for intestinal tissue. As in hu-mice,
non-hu mice TFV showed higher exposures in rectal and intestinal
tissue as a group, with concentrations one to two logs higher
compared to vaginal tissue and plasma (Fig. 1, Table 1). Higher half-
life values of 53 h and 61.6 h in rectal and intestinal tissue respec-
tively were seen in non-hu-mice whereas the t1/2 6.3 h seen in
vaginal tissue was lower than that in hu-mice. The plasma TFV PK
values between hu and non-hu mice at 24 h and 48 h time points
were found to differ signiﬁcantly (po0.05) and no statistically
signiﬁcant difference was found when PK in tissues was compared.
The prodrug TFV is metabolized into its active form TFV-DP
intracellularly in HIV target tissues and cell populations. Accord-
ingly, the levels of TFV-DP were measured in different mucosal
tissues (Fig. 2 and Table 1). In hu-mice, the TFV-DP Cmax was at 2 h
in rectal tissues (604 ng/g) and its AUC24 h was 70,194ng h/g. The
t1/2 of TFV-DP in rectal compartment was 22.2 h. In intestinal
tissue TFV-DP Cmax was 8841 ng/g at 8 h whereas the AUC24 h was
172,167 ng h/g. The intestinal TFV-DP t1/2 was 3.5 h. The TFV-DP
concentrations could not be measured in vaginal tissues consis-
tently as it was detected only once each at 2 h and 24 h. This is in
line with difﬁculties noted in detection of low TFV-DP concentra-
tions in previous human studies (Brown et al., 2011; Vourvahis et
al., 2008). Overall, the intestinal TFV-DP exposure was found to be
higher than in the rectal compartment indicated by the AUC24 h
intestinal:rectal tissue ratio of 2.45. TFV-DP concentrations were
also assessed in non-hu-mice for comparison. The TFV-DP Cmax
was at 24 h in rectal tissue (198 ng/g) and its AUC24 h was
3188 ng h/g. The t1/2 of TFV-DP in rectal compartment could not
be calculated due to no elimination seen at 24 h. In intestinal
tissue, Cmax was 119 ng/g at 8 h, the AUC24 h was 2414 ng h/g and
t1/2 was 45.3 h. Overall, in non-hu mice the rectal TFV-DP exposure
was found to be higher than in the intestinal compartment
indicated by AUC24 h. Similar to that in hu-mice above, TFV-DP
could not be detected in vaginal compartment. TFV-DP PK differ-
ences in hu versus non-hu mice were statistically signiﬁcant
(po0.05) at all time points in both rectal and intestinal compart-
ments with the exception of 2 h in the intestinal tissue.
MVC concentrations in plasma and mucosal tissue compartments
The HIV entry inhibitor MVC acts extracellularly by interfering
with viral binding to the CCR5 co-receptor. In the ﬁrst set of
experiments, non-hu mice were used (5 per each time point)
whereas in the second set of experiments hu-mice (3 per time
point) were used to determine if any differences exists between
the PK values. The drug concentrations were measured in plasma
and vaginal, rectal and intestinal mucosal tissue compartments at
4, 12, and 24 h post-last dose. In addition, plasma concentrations
were also determined at 48 h. The composite PK data on MVC drug
concentrations at various time points in different tissue compart-
ments and plasma are presented in Fig. 3A1 (hu-mice) and A2
(non-hu-mice), whereas the data for individual mice for each of
the compartments are presented in Fig. 3B1–E1 (hu-mice) and
Fig. 3B2–E2 (non-hu-mice). PK parameters Cmax, Tmax, t1/2 and AUC
are shown in Table 2.
MVC was detected in all compartments at all time points
analyzed. For non-hu mice, highest concentrations in plasma
post-last dose were detected at 4 h (Cmax 113 ng/ml). The AUC48 h
for plasma was 3280 ng h/ml. The composite t1/2 in plasma was
20.1 h. In vaginal tissue Cmax was at 4 h (1764 ng/g) with a gradual
elimination up to 12 h. Vaginal tissue AUC24 h was 11,239 ng h/g
and MVC was detected at higher concentrations than in plasma at
4 h, 12 h and 24 h. The t1/2 of MVC in vaginal tissue was 3.7 h.
Rectal tissue MVC kinetics was characterized by Cmax of 3785 ng/g
at 4 h, AUC24 h of 69,301 ng h/g and t1/2 of 2.9 h. In intestinal tissue
MVC Cmax was 18,194 ng/g at 4 h, AUC24 h was 134,883 ng h/g and
t1/2 was 2.7 h. The overall MVC exposure, indicated by AUC24 h was
the highest in intestinal tissue followed by rectal tissue, vaginal
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tissue and plasma. The AUC24 h tissue:plasma ratios for MVC were
3.65 for vaginal, 22.5 for rectal and 43.8 for intestinal tissue.
With regard to PK of MVC in hu-mice versus non-hu mice, the
overall tissue to plasma distribution trends were similar, with intest-
inal tissue showing the highest exposure (AUC24 h 140,159 ng h/g),
followed by rectal tissue (AUC24 h 32,690 ng h/g), vaginal tissue
(AUC24 h 2461 ng h/g) and plasma (AUC24 h 488.6 ng h/ml, AUC48 h
755 ng h/ml), Concentration of MVC at 4 h (Cmax) in hu-mice was
similar to that in non-hu mice in plasma. The MVC concentrations in
rectal and intestinal tissues were higher in hu versus non-hu mice.
Signiﬁcant difference was seen in plasma wherein t1/2 was 20 times
lower in hu versus non-hu mice (1 h versus 20 h), while t1/2 in tissue
compartments was slightly lower. Also, lower drug exposure (AUC24 h)
was seen in hu-mice, with the exception of intestinal tissue. However,
the observed differences in drug concentrations between hu-mice and
non-hu mice were not found to be statistically signiﬁcant (Mann–
Whitney two-tailed test) except at 4 h for intestinal tissue (p o0.05)
and 12 h for vaginal tissue (p o0.05).
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Fig. 2. PK analysis of TFV DP in hu- and non-hu mice. TFV was gavaged as in Fig. 1 above. Intracellular, diphosphorylated metabolite of TFV (TFV-DP) was detected and
quantiﬁed in tissues at different times post-last dose. A1 (hu-mice), and A2 (non-hu mice). Composite median, IQR for TFV DP in rectal and intestinal tissue (colon). B1, C1
(hu mice), B2, C2 (non-hu mice). Individual data points shown (n¼5 hu mice, n¼3 non-hu mice) with composite median, IQR in rectal (B) and intestinal tissue (C).
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Fig. 3. PK analysis of orally administered MVC in hu- and non-hu mice. Mice were administered MVC by oral gavage (human equivalent dose 62 mg/kg) for 5 days. Post-last
dose, plasma and tissue samples were collected at different time points and drug concentrations were determined (ng/ml or ng/g). A1 (hu mice), and A2 (non-hu mice).
Composite medians and interquartile ranges (IQR) for plasma, vaginal, rectal and intestinal tissue (colon). B1–E1 (hu mice), and B2–E2 (non-hu mice). Individual data points
(n¼3 hu-mice, n¼5 non-hu mice) for plasma (B), vaginal (C), rectal (D) and intestinal tissue (colon) (E) with composite medians (IQR) are shown.
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Discussion
Nearly all present PrEP strategies employ currently approved
ARTs for HIV prevention (Thompson et al., 2013). However, the
doses being used for treating the patients do not accurately
represent preventive doses necessary for full protection against
HIV. Therefore, protective drug concentrations at the mucosal
transmission target sites such as vaginal and rectal tissue must
be deﬁned to inform optimal dosing. Derivation of this much
needed data by experimental studies will represent a signiﬁcant
advancement in the PrEP arena.
Here we utilized a humanized mouse model (RAG-hu) suscep-
tible to HIV mucosal transmission to assess the drug concentra-
tions following oral dosing with two leading PrEP candidates with
different modes of action, RT inhibitor TFV and entry inhibitor
MVC. Since concurrent measurements after single dosing may
under or overestimate true tissue exposures due to different
distribution characteristics in tissues compared with plasma, we
measured drug concentrations after multiple dosing at steady
state kinetics (Thompson et al., 2013). Our results showed that
both TFV and MVC can be readily measured in blood plasma,
vaginal, rectal and intestinal tissues. While there were number of
previous studies in the human, this is the ﬁrst experimental study
that simultaneously measured the respective drug concentrations
in multiple mucosal tissues to correlate their values with those in
plasma (Romano et al., 2013; Thompson et al., 2013).
Previous studies on TFV in hu-mice showed protection against
HIV vaginal challenge following systemic and topical drug applica-
tion (Chateau et al., 2013; Denton et al., 2008, 2011). Here with
oral dosing, peak concentrations of TFV were detected at 2 h after
last dose in each of the compartments tested with a terminal
elimination phase at 24–48 h. The TFV half-life in blood plasma in
hu-mice was comparable to that seen in an earlier human trial
(Kearney et al., 2004). The overall drug exposure determined by
AUC24 h for TFV in vaginal tissue was found to be 1.5 higher than in
blood plasma and two logs higher than in blood plasma in rectal
and intestinal tissue. This is further illustrated by the tissue:
plasma AUC24 h ratios (T:P ratio) (Fig. 4), which were 1.5, 99.0
and 141.7 for vaginal, rectal and intestinal tissues respectively,
indicating higher drug exposure in vaginal and rectal tissues
relative to plasma. This observed differential accumulation in
various tissues is in agreement with the data from multiple human
studies and could be due to multiple factors that include distinct
mucosal expression and localization of drug transporters (Nicol et
al., 2013; Romano et al., 2013; Thompson et al., 2013).
Post-uptake, the prodrug TFV is converted intracellularly to its
pharmacologically active form TFV diphosphate (TFV-DP) inhibit-
ing HIV-RT. As seen with its prodrug, the TFV-DP exposure was
also higher in intestinal tissue than in rectal tissue as depicted by
higher AUC24 h (172,167 ng h/g versus 70,194 ng h/g) and T:P ratio
(141.7 versus 99). In contrast, the half-life of TFV-DP was higher in
rectal tissue (22.2 h) compared to the intestinal tissue (3.5 h).
Differences in TFV-DP concentrations in rectal and intestinal
compartments could be due to distinct expression and activity
levels of native kinases needed for TFV to TFV-DP conversion, and/
or differences in tissue expression of drug transporters, in addition
to other factors inﬂuencing the PK of the prodrug TFV (Nicol et al.,
2013; Romano et al., 2013; Thompson et al., 2013).
Consistent with human studies, higher concentrations of TFV
were seen in hu-mouse mucosal tissues compared to blood plasma
(Dumond et al., 2007; Kwara et al., 2008; Vourvahis et al., 2008).
The overall TFV tissue exposures were also similar to that in the
human as depicted by AUC24 h tissue:plasma ratios in vaginal,
rectal and intestinal tissues (Patterson et al., 2011). Sustained TFV
and TFV-DP concentrations were seen in the rectal compartment
similar to a previous human study (Patterson et al., 2011). Long
lasting intracellular TFV-DP levels seen in hu-mice are also akin to
those seen in another previous human trial (Hawkins et al., 2005).
The extended half-life seen in the rectal tissue is advantageous for
protection in MSM and this was documented in iPrEX study
wherein it was found that individuals that did not fully comply
Table 2
PK parameters for maraviroc in humanized and non-humanized mice.
MVC (hu-mice) Plasma Vaginal tissue Rectal tissue Intestinal tissue
Cmax
a 102 459 7577 33,462
Median (IQR) (46–109) (228–659) (5492.6–9769) (31,958–36,819)
Tmax 4 h 4 h 4 h 4 h
AUCb 755 2461 32,690 140,159
t ½c 1 2.6 1.5 1.2
MVC (non-hu mice)
Cmax
a 113 1764 3785 18,194
Median (IQR) (43–797) (403–1982) (2329–8,512) (9893–22,980)
Tmax 4 h 4 h 4 h 4 h
AUCb 3280 11,239 69,301 134,883
t ½c 20.1 3.7 2.9 2.7
a Median (interquartile range, IQR), ng/ml or ng/g.
b Area under the curve (AUC)48 h for plasma (ng h/ml); AUC24 h for tissues (ng h/g).
c Half-life (t½, h).
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Fig. 4. Tissue to blood plasma AUC24 h ratios of TFV. Tissue to plasma ratios were
calculated for AUC24 h. On the y axis, 1 indicates a line of unity, where mucosal
tissue exposure is similar to blood plasma. Values above the line of unity indicate
higher drug exposure at mucosal sites compared to plasma. VT-vaginal tissue,
RT-rectal tissue, and IT-intestinal tissue (colon).
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with daily recommended dosing were still protected from HIV
infection (Grant et al., 2010). These ﬁndings taken together suggest
that overall, the relative PK trends of TFV and its active metabolite
TFV-DP in hu-mice are similar to that seen in human studies and
clinical trials. Moreover, the hu-mice data further conﬁrm the
favorable PK proﬁle of TFV for its use as a PrEP agent.
With regard to the PK proﬁles of TFV and TFV-DP in hu- versus
non-hu mice, while the overall AUC24 h trends were similar with
drug concentrations being higher in intestinal, rectal tissues than
in plasma, differences were also noted in tissue exposure levels,
Tmax and t1/2. For example, the TFV AUC24 h tissue:plasma ratios in
vaginal and intestinal tissue of hu-mice were 2 fold higher
compared to non-hu mice whereas t1/2 was longer in rectal and
intestinal tissue of non-hu mice (53 h and 61.6 h, respectively)
relative to that in hu-mice (13.5 h and 13.9 h). With TFV-DP, one
to two log higher AUC24 h was seen in rectal and in intestinal tissues
of hu-mice whereas it's t1/2 was longer in non-hu mice in both
intestinal (45.3 h versus 3.5 h) and rectal (no elimination phase was
detected by 24 h, compared to 22.2 h t1/2 in hu-mice) compartments
compared to hu-mice (Table 1). While not entirely clear, the
observed PK differences between hu- versus non-hu mice can be
partly attributed to the absence of circulating lymphoid cell popula-
tion, and thus drug clearance in the blood compartment as well as
the mucosal tissues of non-humanized mice.
With respect to the entry inhibitor MVC, we have previously
shown that its oral administration at allometric dosing levels is fully
protective against HIV vaginal challenge in hu-mice (Neff et al.,
2010). MVC exerts its antiviral action extracellularly in contrast to
the RT inhibitor TFV which gets converted to its active form
intracellularly. Therefore, in our initial experiments we analyzed
MVC concentrations in non-hu mice. Maximum MVC concentra-
tions were reached at 4 h in plasma and in all the mucosal tissues.
The highest exposure to MVC was seen in intestinal tissue (AUC24 h
T:BP ratio of 43.8), followed by rectal and vaginal tissue (AUC24 h
ratios of 22.5 and 3.6) The PK trends seen here were comparable to
those in human studies (Brown et al., 2011; Dumond et al., 2009). As
indicated by AUC24 h tissue:plasma ratios, there were higher expo-
sures in vaginal and rectal tissue compartment to that in blood
plasma, similar to that seen in previous human clinical trials (Brown
et al., 2011; Dumond et al., 2009). In addition, blood plasma Tmax,
elimination rate and AUC12 h were similar to those found in human
studies (Abel et al., 2008; Dumond et al., 2009). Sustained high
rectal drug concentrations up to 12 h correlated well with those
found in an earlier human study (Brown et al., 2011).
We next determined the MVC pharmacokinetics in hu-mice to
see if any differences exist when compared with non-hu mice.
Similar to the results seen in non-hu mice, maximum drug
concentrations were reached at 4 h in all compartments analyzed.
Higher drug exposure (AUC24 h) was also detected in rectal and
intestinal tissues compared to vaginal tissue. However a signiﬁcant
difference was the much shorter half-life seen in blood plasma of
hu-mice versus non-hu mice (1 h versus 20 h). This could be
attributable to MVC binding to the CCR5 co-receptor on human
cells in the blood and tissue compartments of hu-mice. AUC24 h in
plasma, vaginal and rectal tissues in non-hu-mice were found to
be higher than in hu-mice most likely due to the absence of
human cells that would have sequestrated most of the drug in the
blood cellular compartment. Higher tissue:plasma AUC24 h ratios
were seen in hu-mice compared to non-hu mice for all tissues
(Fig. 5). This is not unexpected due to lower plasma MVC half-life
seen in hu-mice. Relative to that seen in human studies, the
AUC24 h tissue:plasma ratios were found to be higher in hu-mice.
For vaginal tissue, MVC AUC24 h VT:BP ratio was 5 in hu-mice
compared to 1.9 seen in the human whereas in rectal tissue, the
RT:BP AUC ratio was 66.9 relative to the 8–26 range seen in the
human. Nevertheless, the overall MVC exposure trends of higher
drug concentrations seen in mucosal tissues versus blood plasma
are similar between hu-mice and human. The vaginal concentra-
tion of MVC necessary for full HIV prevention in human clinical
studies is not currently known. Therefore the concentrations
measured in hu-mice wherein MVC was shown to be fully
protective against HIV vaginal challenge should inform future
dosing strategies in the human (Neff et al., 2011). The overall
excellent oral bioavailability and high genital tract exposure of
MVC relative to plasma as demonstrated in these studies lends
further support for it being an ideal candidate for oral PrEP.
However in comparison with TFV and its active metabolite TFV-
DP, MVC half-life in tissue compartments is much shorter and thus
will require consistent dosing and more patient compliance in
terms of adherence.
For both ARVs analyzed, drug concentrations varied widely
between individual mice at some time points although the
composite PK trends were similar. This is not unlike that observed
in previous NHP and human studies wherein a wide degree of
inter and intra-subject variability was seen (Brown et al., 2011;
Dumond et al., 2009, 2007; Evans and Silvestri, 2013; Fennessey
and Keele, 2013; Patterson et al., 2011; Vourvahis et al., 2008).
While we used hu-mice with robust human cell reconstitution,
their levels in individual mice could have partly played a role.
However, this appears unlikely since wide variations in drug
concentrations were seen in non-hu-mice as well.
With regard to the PK studies like these in the PrEP context, the
importance of using hu-mice versus non-hu-mice is apparent. This
is illustrated by differences such as MVC plasma half-life being
lower in hu-mice compared to non-hu mice. In addition for
compounds such as TFV which function intracellularly after phos-
phorylation, use of hu-mice harboring human cells is also more
appropriate. Based on the overall data from above, hu-mice suscep-
tible to HIV mucosal transmission can be exploited to assess ARV PK
parameters. In addition to complementing results from NHP mod-
els, data derived in hu-mice on novel drugs would help inform
more detailed subsequent NHP studies where appropriate. Drug
concentrations determined to confer protection against HIV itself in
hu-mice can be extrapolated to the human to inform HIV preven-
tion doses of novel ARVs for prophylactic purposes.
Since the use of a single drug may not be adequate to confer full
protection in a global setting, future oral HIV PrEP strategies will
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most likely involve a combination of ARVs with different mechan-
ism of action for complete efﬁcacy. However, whether the combi-
natorial ARVs would retain similar tissue distribution and overall
kinetics compared to when applied singly needs to be determined.
Such combinatorial studies can be conducted in hu-mice to deﬁne
PK/PD parameters of various multi-drug regimen approaches to
assess potential additive, synergistic and antagonistic effects
between different classes of ARVs. In addition, adherence issues
of PrEP use and efﬁcacy can also be simulated in hu-mice to derive
useful preclinical data (Adams et al., 2013). It is also clear from the
present data and previous reports that drug distribution and
kinetics in different tissues vary (Romano et al., 2013; Thompson
et al., 2013). This could be due to multiple factors which include
target cell drug inﬂux and efﬂux properties, differential mucosal
expression and distribution of speciﬁc drug transporters and
distinct expression of cytochrome P450 (CYP) and other drug
metabolizing enzymes in mucosal compartments (Nicol et al.,
2013; To et al., 2013). Such parameters can be experimentally
evaluated in the humanized mouse model in the context of the
human immune cell populations targeted by HIV. The preclinical
knowledge gained from such in vivo studies addressing these
questions will be very useful for more informed clinical trials of
new PrEP strategies
Materials and methods
Generation of humanized mice
Humanized BALB/c Rag1/ or Rag2/γc/ (Hu-HSC RAG-
hu) mice were generated by engrafting human fetal liver-derived
CD34þ hematopoietic progenitor cells (HPC) as previously
described (Berges et al., 2008, 2006). Mice were maintained at
the Colorado State University Painter Animal Center and all studies
were approved by the CSU Institutional Animal Care and Use
Committee (Protocol 11-3153A). Newborn mice were precondi-
tioned by irradiating with a sub-lethal dose of 350 rads and then
injected intrahepatically with 0.5–1106 human CD34þ cells.
Mice were screened for human cell engraftment at 10–12 weeks
post-reconstitution. Peripheral blood was collected by tail bleed
and red blood cells were lysed by the Whole Blood Erythrocyte
Lysing Kit (R&D Systems, Minneapolis, MN). The white blood cell
fraction was stained against the human pan-leukocyte marker
CD45 using hCD45-R-PE (Invitrogen) and FACS analyzed to deter-
mine the levels of human cell engraftment as previously reported
(Berges et al., 2008; Berges et al., 2006). Mice with more than 50%
human cell engraftment were used for experiments involving hu-
mice to assure robust numbers of human cells being present.
Drug administration of antiretrovirals and sample collection
Female mice were administered with either Tenofovir or
maraviroc by oral gavage. Clinical formulations of these drugs in
tablet form (Maraviroc (Selzentry) 150 mg, Pﬁzer Labs; Tenofovir
disoproxil fumarate (Viread) 300 mg, Gilead Sciences), were
freshly dissolved in sterile PBS prior to oral gavage. Mouse
equivalent drug doses were calculated by using an interspecies
allometric scaling factor of 12.3 to arrive at 61.5 mg/kg and 62 mg/
kg doses for TFV and MVC respectively. Mice (three or ﬁve per
group) received either TFV (1.23 mg per 20 g mouse) or MVC
(1.24 mg per 20 g mouse) by oral gavage daily for 5 days. Plasma
and tissue samples were collected for each drug following the last
gavage at 2 h, 8 h, and 24 h for TFV and at 4 h, 12 h and 24 h for
MVC. In addition, 48 h plasma samples were collected for one
group each of treated animals. All samples except 48 h blood
plasma were terminal and were collected during mouse
necropsies. Tissue samples collected after drug administration
consisted of vaginal, rectal and intestinal tissue samples. Tissue
and plasma samples were snap frozen in liquid nitrogen within
ﬁve minutes from the time of tissue collection. For negative
controls, plasma and tissue samples were collected from untreated
mice and were processed using the protocols described above.
Samples were stored at 80 1C until drug measurements.
Measurement of drug concentrations in plasma and tissue samples
Quantiﬁcation of analytes was similar to previously published
methods (Brown et al., 2011). Brieﬂy, quantiﬁcation of TFV con-
centrations in plasma was performed by protein precipitation and
LC–MS/MS analysis with an isotopically-labeled internal standard
(13C TFV). TFV was eluted from a Waters Atlantis T3 (100 
2.1 mm, 3 mm particle size) analytical column and an API-5000
triple quadrupole mass spectrometer (AB Sciex, Foster City, CA)
was used to detect the analytes. Data were collected using AB Sciex
Analyst Chromatography Software (Analyst version 1.6.1). The
dynamic range of this assay was 1–1000 ng/mL using a 1/concen-
tration2 weighted linear regression.
For measuring concentrations in mucosal tissues, TFV and
TFV-DP was extracted from tissue homogenate by protein pre-
cipitation with isotopically-labeled internal standards (13C TFV and
13C TFV-DP). TFV was eluted from a Waters Atlantis T3
(1002.1 mm2, 3 mm particle size) analytical column, and TFV-
DP was eluted from a Thermo Biobasic AX (502.1 mm2, 5 mm
particle size) analytical column. An API-5000 triple quadrupole
mass spectrometer was used to detect all analytes. Data were
collected using AB Sciex Analyst Chromatography Software (Ana-
lyst version 1.6.1). The dynamic range of this assay was 0.3–
300 ng/mL of homogenate for each compound using a 1/concen-
tration2 weighted linear regression. Concentrations were ulti-
mately converted into ng/mg (TFV) or fmol/mg (TFV-DP) tissue
for ﬁnal reporting.
To measure drug concentrations in plasma, MVC was extracted
from samples using solid phase extraction with Varian BondElut
C-18, 100 mg, 1CC cartridges. Plasma samples were quantiﬁed
against the internal standard, alprazolam, on an Agilent 1200
series HPLC system using a Zorbax Eclipse XDB (504.6 mm2,
1.8 mm particle size) analytical column. An Agilent 1100 MSD was
used to detect the analyte and internal standard. The dynamic
range of this assay was 1–1000 ng/mL.
For quantiﬁcation from mucosal tissues, MVC was extracted
from tissue homogenates using protein precipitation with the
internal standard alprazolam. This resulting extract was analyzed
on an Agilent 1200 series HPLC system using a Zorbax Eclipse XDB
(504.6 mm2, 1.8 mm particle size) analytical column. An Agilent
1100 MSD was used to detect the analyte and internal standard.
The dynamic range of this assay was 0.007–7 ng/mg.
Statistical analysis
GraphPad Prism version 5 (GraphPad Software, USA) software
was used for data analysis, ﬁgure generation, calculation of PK
parameters and statistical analysis. PK data for TFV, TFV-DP and
MVC in hu and non-hu mice were compared using Mann–Whitney
two-tailed test. P values o0.05 were considered as signiﬁcant.
Measures of central tendency were expressed as median and inter-
quartile range (IQR 25th, 75th percentile).
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